Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS986260是一种口服有活力的选择性TGFβR1抑制剂,是免疫肿瘤学药物。它能够抑制 MINK 和 NHLF 细胞系中 TGFβ 介导的 pSMAD2/3 核转位,IC50值分别为 350 nM 和 190 nM。它对 TGFβR1 的选择比 TGFβR2 同功酶高。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 825 | 现货 | ||
5 mg | ¥ 1,980 | 现货 | ||
10 mg | ¥ 2,970 | 现货 | ||
25 mg | ¥ 4,930 | 现货 | ||
50 mg | ¥ 6,880 | 现货 | ||
100 mg | ¥ 9,270 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,980 | 现货 |
产品描述 | BMS-986260 is a selective, and orally bioavailable TGFβR1 inhibitor(IC50 = 1.6 nM). |
体外活性 | BMS-986260 demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models. Since daily dosing of TGFβR1 inhibitors is known to cause class-based cardiovascular (CV) toxicities in preclinical species, a dosing holiday schedule in the anti-PD-1 combination efficacy studies was explored. An intermittent dosing regimen of 3 days on and 4 days off allowed mitigation of CV toxicities in one month dog and rat toxicology studies and also provided similar efficacy as once daily dosing. |
分子量 | 382.78 |
分子式 | C18H12ClFN6O |
CAS No. | 2001559-19-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (65.31 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6125 mL | 13.0623 mL | 26.1247 mL | 65.3117 mL |
5 mM | 0.5225 mL | 2.6125 mL | 5.2249 mL | 13.0623 mL | |
10 mM | 0.2612 mL | 1.3062 mL | 2.6125 mL | 6.5312 mL | |
20 mM | 0.1306 mL | 0.6531 mL | 1.3062 mL | 3.2656 mL | |
50 mM | 0.0522 mL | 0.2612 mL | 0.5225 mL | 1.3062 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BMS986260 2001559-19-7 Stem Cells TGF-beta/Smad nuclear translocation TGFβR1 FOXP3 expression MINK Transforming growth factor beta receptors BMS-986260 oral NHLF cells inhibit Inhibitor CD25 TGF-β Receptor pSMAD2/3 selective BMS 986260 inhibitor